NeOnc Technologies Holdings (NASDAQ:NTHI) is rapidly emerging as a development-stage neuro-oncology innovator, as it advances a growing pipeline of therapies designed to address some of the most difficult cancers to treat.

Its critical data efforts received a significant boost after the company announced that the Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, NeOnc's oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors, including glioblastoma.

The authorization marks the first international regulatory clearance for NEO212 and follows completion of the company's Phase 1 dose-escalation study, which established 610 mg as the recommended Phase 2 dose. The approval provides NeOnc with an additional clinical development pathway outside the United States while management continues active discussions with the U.S. Food and Drug Administration regarding a potential registrational strategy and future development plans. Many experts view the parallel regulatory tracks as a potentially important strategic advantage as the company seeks to accelerate global development efforts.